VBL Therapeutics Reports Radiographic Analysis of VB-111 Phase 2, 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity
Benzinga Newsdesk